Sermorelin
A growth hormone-releasing hormone analog that was previously FDA-approved for diagnosing GH deficiency in children.
What is Sermorelin?
Sermorelin is a synthetic peptide consisting of the first 29 amino acids of naturally occurring growth hormone-releasing hormone (GHRH). It was previously FDA-approved (as Geref) for diagnostic use in evaluating growth hormone deficiency in children. While the branded product was discontinued for commercial reasons, sermorelin remains available through compounding pharmacies and is one of the most well-studied growth hormone peptides.
What Sermorelin Is Investigated For
Sermorelin is investigated for pediatric growth hormone deficiency, adult GH optimization, sleep quality, and body composition — and the strongest evidence is for pediatric GH-deficiency treatment, the indication that earned it FDA approval as Geref in 1997 with a robust Serono-era clinical dataset. Its adult off-label use for sleep, body composition, and anti-aging rests on mechanistically sound but modern-era-thin evidence: the pediatric data predates the current treatment landscape, dedicated dose-ranging trials in healthy adults do not exist, and most adult protocols are empirical extensions of the pediatric label. Honest caveats include that the Geref brand was withdrawn in 2008 (for commercial, not safety, reasons), current access is via compounding pharmacies under uncertain long-term 503A status, and the IGF-1-mediated downstream pharmacology carries the same theoretical long-term concerns as exogenous GH even though pulsatility is preserved. Sermorelin is also explicitly prohibited under WADA's S2 category regardless of its prior approval history.
History & Discovery
Sermorelin is the synthetic 1–29 amino acid fragment of human growth hormone-releasing hormone (GHRH), and its development traces back to the pioneering work of Roger Guillemin at the Salk Institute in the early 1980s. Guillemin's group — building on the discovery that GHRH could be isolated from pancreatic tumors in acromegalic patients — characterized the full 44-amino-acid GHRH sequence and demonstrated that the N-terminal 1–29 fragment retained full biological activity. This observation was the basis for developing sermorelin as a shorter, synthesizable therapeutic. Serono Laboratories (the Swiss-based pharmaceutical company, later part of Merck KGaA) developed sermorelin as a commercial product under the brand name Geref, securing FDA approval in 1997 for two indications: diagnostic evaluation of pituitary GH reserve, and therapeutic treatment of idiopathic growth hormone deficiency in children. The approval made sermorelin one of the few GH secretagogues to ever clear the FDA bar — a distinction the newer CJC-1295 and ipamorelin have not achieved. Geref was voluntarily withdrawn from the US market by Serono in 2008. The withdrawal was not prompted by safety concerns; it was a commercial decision driven by the rise of recombinant human GH (rhGH), which offered more predictable pediatric-growth outcomes than a secretagogue that required intact pituitary function. After withdrawal, sermorelin remained available through state-licensed compounding pharmacies, where it has been widely prescribed for off-label adult indications (anti-aging, body composition, sleep) that were never part of its FDA label. The FDA's 2023 review of peptides eligible for 503A compounding has created uncertainty about sermorelin's compounding-pharmacy access going forward, though at the time of writing it remains more securely available through that channel than CJC-1295 or ipamorelin — in part because it has a genuine history of FDA approval and a larger clinical safety dataset.
How It Works
Sermorelin is essentially a copy of the natural signal your brain sends to release growth hormone. By providing this signal, it encourages your pituitary gland to produce more growth hormone naturally, rather than injecting growth hormone directly.
Sermorelin binds to the GHRH receptor on anterior pituitary somatotrophs, activating adenylyl cyclase and increasing intracellular cAMP. This promotes both the synthesis and secretion of growth hormone. Unlike exogenous GH, sermorelin preserves the hypothalamic-pituitary feedback loop, maintaining physiological pulsatile GH release patterns. It has been shown to increase both GH pulse amplitude and frequency.
Evidence Snapshot
Human Clinical Evidence
Strong. Extensive clinical data from its period as an FDA-approved diagnostic agent, plus additional clinical studies.
Animal / Preclinical
Strong. Well-characterized pharmacology.
Mechanistic Rationale
Very strong. GHRH receptor pharmacology is thoroughly understood.
Research Gaps & Open Questions
What the current literature has not yet settled about Sermorelin:
- 01Modern long-term adult safety and efficacy data is thin — the pediatric Geref clinical dataset is robust but dates from the 1990s and early 2000s, while current off-label adult wellness use has no comparable contemporary dataset.
- 02Pediatric GHD clinical data is decades old and predates the current treatment landscape in which rhGH is the default standard of care; modern head-to-head comparisons with rhGH are limited.
- 03Whether sermorelin's preserved pulsatility translates to a meaningfully different long-term safety margin vs. exogenous rhGH at comparable IGF-1 exposure is a compelling argument mechanistically but has not been tested in long-duration comparative endpoint trials.
- 04Optimal adult dosing for non-deficiency indications (anti-aging, body composition, sleep) has never been established in a dedicated dose-ranging trial — adult protocols are empirical extensions of the pediatric label.
- 05Combination dosing (sermorelin + GHRP) has pharmacological rationale but very limited controlled human outcome data.
- 06Compounding-pharmacy sourcing variability — active pharmaceutical ingredient purity and reconstitution practices vary across pharmacies, and this quality-control variance is not well characterized in published literature.
Forms & Administration
Sermorelin is administered via subcutaneous injection, typically before bedtime. Protocols should be determined by a qualified clinician with appropriate lab monitoring.
Dosing & Protocols
The ranges below reflect protocols commonly discussed in the literature and by clinicians — not a prescription. Actual dosing for any individual should be determined by a qualified healthcare provider who knows the patient.
Typical Range
The historical Geref pediatric label used 0.03 mg/kg subcutaneous daily at bedtime. Commonly referenced adult wellness protocols run 200–500 mcg once daily at bedtime, with 300 mcg being a frequently cited middle-of-the-range dose. Some protocols use up to 1 mg per injection in split dosing (morning and evening). Doses above ~1 mg per injection do not produce proportionally greater GH release due to the bell-shaped dose-response curve.
Frequency
Sermorelin has a short half-life (~10–20 minutes in humans) — it is cleared rapidly by DPP-IV and other peptidases. This short half-life is actually a feature for the 'physiological pulse' argument: a single bedtime injection produces one discrete GH pulse that aligns with the natural nocturnal GH surge, then clears before it can cause sustained receptor occupancy. The stacking rationale with a GHRP (ipamorelin, GHRP-2, GHRP-6) rests on the same dual-pathway logic as CJC-1295 + ipamorelin stacks: sermorelin primes somatotrophs via the GHRH receptor while the GHRP triggers release via the GHS-R1a receptor. Some adult protocols include a GHRP at the same injection time; others use sermorelin as monotherapy.
Timing Considerations
Time of day
Bedtime is the standard window — sermorelin's short half-life and the timing of the natural nocturnal GH pulse make pre-sleep dosing the most biologically effective.
Relative to meals
Fasted is preferable: at least 30 minutes before food and 2+ hours after a meal. Elevated insulin and amino acids blunt the pituitary GH response.
Relative to exercise
Unrelated to training. Sermorelin is rarely used as a pre-workout peptide because its GH pulse aligns more naturally with sleep-phase physiology.
Cycle Length
Commonly discussed adult protocols run 3–6 months on, with breaks of 1–2 months, though continuous use is also described. In the pediatric Geref literature, children were treated continuously for 6–12 months and longer with periodic reassessment of growth velocity. Sermorelin is less commonly cycled than MK-677 because its short half-life and preservation of pulsatility argue against tachyphylaxis — but long-duration adult data at off-label doses is thin.
Protocol Notes
Sermorelin is supplied as a lyophilized powder, typically in 3 mg or 5 mg vials. Reconstitution in bacteriostatic water is standard — a 5 mg vial in 2 mL yields 2,500 mcg/mL, making 300 mcg approximately 0.12 mL on an insulin syringe. Subcutaneous injection into the abdominal fat pad is the standard route. Bedtime dosing is strongly preferred because it aligns with the body's endogenous nocturnal GH pulse, amplifying rather than competing with natural secretion, and because elevated insulin from daytime meals blunts the GH response. Injection on an empty stomach (≥2 hours after the last meal) maximizes the GH pulse. Unlike CJC-1295 DAC, sermorelin requires daily injection because of its short half-life — this is sometimes framed as a disadvantage, but the dose fidelity and fast clearance are what preserve physiological pulsatility.
Sermorelin was FDA-approved (as Geref) for pediatric GH deficiency diagnosis and treatment; the branded product was withdrawn in 2008. Current compounding-pharmacy availability is for off-label adult use and is not the same as an active FDA approval. Use should be supervised by a qualified clinician with appropriate lab monitoring.
Timeline of Effects
Onset
Sleep quality — particularly deeper slow-wave sleep — is the most reliably reported early benefit, typically within 1–2 weeks of initiating bedtime dosing. Subjective recovery improvements follow in a similar window. Body-composition changes are slower: modest fat-mass reduction and lean-mass preservation typically require 2–3 months of consistent use. Skin-quality changes (improved thickness, hydration) are commonly reported around the 3-month mark.
Peak Effect
Serum IGF-1 rises progressively over the first 4–8 weeks and plateaus. The magnitude of IGF-1 elevation with sermorelin monotherapy is typically modest compared to MK-677 or CJC-1295 DAC — reflecting its short half-life and single-pulse-per-day profile. Subjective benefits plateau around 3 months. In the pediatric Geref data, growth-velocity response was most pronounced in the first year.
After Discontinuation
Short half-life and non-suppression of endogenous GHRH mean pulsatile GH returns to baseline within 1–3 days of discontinuation. IGF-1 drifts back to pre-treatment levels over 2–4 weeks. Any accumulated body-composition or sleep benefits wane over weeks to a few months. No HPG-axis suppression and no post-cycle therapy required. The reversibility profile is among the cleanest of any GH-axis intervention, which is part of sermorelin's long-standing safety reputation.
Monitoring & Measurement
Bloodwork & Labs
- •IGF-1 (serum) — the practical response marker
- •Fasting glucose and HbA1c — sermorelin's glycemic impact is typically minimal, but worth confirming
- •Lipid panel
Functional & Performance Tests
- •DEXA scan for body composition
- •Waist circumference
- •Overnight sleep quality via wearable
When to Test
Baseline, 8 weeks, and 16 weeks — sermorelin's ramp is slower than other GHRH analogs.
Interpretation & Notes
Sermorelin is the gentlest of the commonly used GHRH analogs. Expect modest IGF-1 rises of 15–30% at typical doses, and glycemic impact is usually minimal. If you see no IGF-1 change at 12 weeks on a therapeutic dose, two explanations are likely before 'non-responder': a low-potency or degraded batch (sermorelin's short half-life makes it especially sensitive to reconstitution and cold-chain handling), or an intact-pituitary assumption that doesn't hold — sermorelin cannot drive GH release in patients with primary pituitary insufficiency. Sermorelin is frequently stacked with GHRPs (ipamorelin, GHRP-2) for additive effect; track IGF-1 under stacked and solo conditions separately to interpret responsibly. Panels available direct-to-consumer.
Common Questions
Who Sermorelin Is NOT For
- •Active or recent-history cancer — GH and IGF-1 elevation may accelerate proliferation of existing malignancies; clinicians exclude active cancer from sermorelin protocols.
- •Pregnancy — no adequate human pregnancy safety data; Geref was labeled Pregnancy Category C.
- •Breastfeeding — excretion into breast milk is not characterized.
- •Diabetes or uncontrolled insulin resistance — GH opposes insulin action; sermorelin's GH effect is milder than MK-677's but glycemic monitoring is prudent.
- •Hypothyroidism (uncontrolled) — reduces GH response and should be corrected before initiating sermorelin.
- •Active acromegaly or pituitary adenoma — further stimulation of GH-producing cells is contraindicated.
- •Severe obesity — can blunt GH response; efficacy may be reduced even if sermorelin is not strictly contraindicated.
- •Known hypersensitivity to sermorelin, mannitol (historical Geref excipient), or compounded preparation excipients.
- •Uncontrolled hypertension or severe sleep apnea — GH-mediated fluid retention and airway effects can worsen both.
Drug & Supplement Interactions
Sermorelin has more characterized drug-interaction data than CJC-1295 or ipamorelin because it was an approved drug with a formal label. Glucocorticoids (prednisone, dexamethasone, hydrocortisone) blunt somatotroph response and attenuate sermorelin's GH-releasing effect — patients on chronic glucocorticoid therapy may see reduced efficacy. Somatostatin analogs (octreotide, lanreotide) directly antagonize GHRH signaling and will pharmacologically oppose sermorelin. Thyroid hormone replacement status matters: uncorrected hypothyroidism reduces GH response, so thyroid function should be optimized before initiating sermorelin. Insulin, sulfonylureas, and other glucose-regulating agents may require dose adjustment as GH/IGF-1 rise, because GH opposes insulin action. Oral estrogens reduce hepatic IGF-1 generation and can blunt apparent lab responses — relevant when using IGF-1 to monitor response. Antimuscarinic agents (atropine and similar) can blunt GH responses to GHRH in some studies. Cholinergic agonists (e.g., pyridostigmine) can modestly enhance the GH response to sermorelin by reducing endogenous somatostatin tone — this pairing is occasionally discussed in clinical protocols. Disclose all concurrent medications to the prescribing clinician.
Safety Profile
Common Side Effects
Cautions
- • Requires clinician supervision
- • Monitor with IGF-1 levels
- • Not for those with active malignancies
What We Don't Know
While short-term safety is well established, long-term effects of sustained use for anti-aging purposes are less characterized.
Legal Status
United States
Sermorelin's FDA approval as Geref was voluntarily withdrawn by Serono in 2008 for commercial reasons — it is no longer an active FDA approval. Sermorelin remains available through state-licensed compounding pharmacies under individualized prescription for off-label adult use, and its compounding access is notably more secure than for most other peptide secretagogues: in the April 15, 2026 FDA action that removed 12 peptides from Category 2 (BPC-157, TB-500, GHK-Cu, MOTS-c, DSIP, Dihexa, MK-677, Melanotan II, KPV, Semax, LL-37, Epitalon), sermorelin's pre-existing Category 1 status was unaffected. It is not on the July 23–24, 2026 PCAC review docket and has not been the subject of recent FDA enforcement. Relative to competing GH-axis peptides, sermorelin's 503A pathway is the most settled in the current regulatory landscape.
International
The European Medicines Agency and UK MHRA have not reinstated any current sermorelin approval. Australia's TGA classifies GH secretagogues and GHRH analogs as Schedule 4 prescription-only substances. Canada and most EU member states treat sermorelin as an unapproved drug for adult wellness indications, though pediatric GH-deficiency use may be permitted through individual compounding arrangements.
Sports & Competition
Sermorelin is explicitly prohibited under WADA's S2 category (Peptide Hormones, Growth Factors, Related Substances and Mimetics), which covers GHRH and its analogs — prohibited at all times, both in and out of competition. LC-MS/MS detection methods exist and sermorelin use has been identified in sanctioned athletes. The fact that sermorelin once had FDA approval does not exempt it from WADA's prohibition.
Regulatory status changes over time. Verify current local rules with a qualified professional.
Myths & Misconceptions
Myth
Sermorelin is currently FDA-approved.
Reality
Sermorelin, as Geref, was FDA-approved in 1997 but was voluntarily withdrawn from the US market by Serono in 2008 for commercial reasons. There is no active FDA approval as of 2026. Current access is through compounding pharmacies for off-label adult use, which is a different regulatory category than an active approved drug.
Myth
Sermorelin was pulled from the market for safety reasons.
Reality
The 2008 withdrawal was a commercial decision by Serono. Sermorelin had accumulated a reasonable safety profile over its years as Geref — the withdrawal reflected the commercial dominance of recombinant human GH in the pediatric GHD space, not an adverse-event signal.
Myth
Sermorelin is 'safer' than HGH and therefore has no real cancer or metabolic risk.
Reality
Sermorelin preserves pulsatility and feedback regulation better than flat exogenous rhGH, which plausibly reduces some side-effect risk. But the downstream mediator is IGF-1, and the theoretical long-term cancer-promotion and metabolic concerns associated with sustained IGF-1 elevation attach to sermorelin too. 'Safer in degree' is not 'safe in kind.'
Myth
Because sermorelin was FDA-approved, it's allowed in sports.
Reality
WADA's S2 category prohibits GHRH and its analogs without regard to regulatory approval status. Sermorelin is explicitly covered. A prior FDA approval for pediatric GHD diagnosis does not create a sports-use exemption. Athletes have been sanctioned for sermorelin use.
Myth
Sermorelin works just as well in people with damaged pituitaries as exogenous HGH does.
Reality
This is why Serono's Geref was marketed specifically for patients with intact pituitary function whose GH deficiency was hypothalamic rather than pituitary in origin. In patients with damaged or absent somatotrophs, sermorelin cannot induce GH release — there are no receptive cells to respond. This limitation is exactly why rhGH displaced sermorelin in most pediatric GHD populations.
Published Research
30 studiesTherapeutic Peptides in Orthopaedics: Applications, Challenges, and Future Directions.
A potentially effective drug for patients with recurrent glioma: sermorelin.
Beyond the androgen receptor: the role of growth hormone secretagogues in the modern management of body composition in hypogonadal males.
Sermorelin: a better approach to management of adult-onset growth hormone insufficiency?
Influential review arguing that sermorelin's preservation of the natural GH pulsatile pattern and feedback mechanisms makes it a safer, more physiological alternative to exogenous GH replacement in adults with age-related GH decline.
Sermorelin: a review of its use in the diagnosis and treatment of children with idiopathic growth hormone deficiency.
Definitive clinical review covering sermorelin's pharmacology, diagnostic utility, and therapeutic use in pediatric GH deficiency, summarizing the evidence base that supported its FDA approval as Geref for both diagnostic and therapeutic indications.
Site-specific PEGylation for high-yield preparation of Lys(21)-amine PEGylated growth hormone-releasing factor (GRF) (1-29) using a GRF(1-29) derivative FMOC-protected at Tyr(1) and Lys(12)
Interactions of GRF(1-29)NH2 with plasma proteins and their effects on the release of the peptide from a PLAGA matrix
Once daily subcutaneous growth hormone-releasing hormone therapy accelerates growth in growth hormone-deficient children during the first year of therapy. Geref International Study Group
Pivotal multicenter trial (Geref International Study Group) demonstrating that once-daily sermorelin significantly accelerated growth velocity in GH-deficient children during the first year of therapy, forming a key part of the clinical data supporting FDA approval of Geref.
The involvement of dipeptidyl peptidase IV in brush-border degradation of GRF(1-29)NH2 by intestinal mucosal cells
Histamine release on rat pleural and peritoneal mast cells elicited by human GRF(1-29)NH2
Study of the activation mechanism of human GRF(1-29)NH2 on rat mast cell histamine release
[Influence of twice-daily injections of GRF 1-29 on production, feed intake and nutritional status of lactating goats]
Secondary structure of the human growth hormone releasing factor (GRF 1-29) by two-dimensional 1H-nmr spectroscopy
[Effects of GRF 1-29 in normal and hypotrophic lambs]
Growth hormone responses to GRF 1-29 in patients with primary hypothyroidism before and during replacement therapy with thyroxine
Structural requirements for the activation of rat anterior pituitary adenylate cyclase by growth hormone-releasing factor (GRF): discovery of (N-Ac-Tyr1, D-Arg2)-GRF(1-29)-NH2 as a GRF antagonist on membranes
The synthetic peptide GRF (1-29)-NH2 with growth hormone releasing activity penetrates human epidermis in nitro
GH response to GRF (1-29) NH2 in female rats treated neonatally with estradiol benzoate or testosterone propionate
Applications of BOP reagent in solid phase synthesis. Advantages of BOP reagent for difficult couplings exemplified by a synthesis of [Ala 15]-GRF(1-29)-NH2
[Response of growth hormone to GRF(1-29)NH2 in 12 cases of active acromegaly]
Testing with growth hormone-releasing factor (GRF(1-29)NH2) and somatomedin C measurements for the evaluation of growth hormone deficiency
The effects of intranasal insufflation of growth hormone releasing factor analogue GRF 1-29 NH2 on growth hormone secretion in children with short stature
Lack of effect of muscarinic cholinergic blockade on the GH responses to GRF 1-29 and TRH in acromegalic subjects
Influence of dopaminergic, adrenergic and cholinergic blockade and TRH administration on GH responses to GRF 1-29
Does growth hormone releasing factor desensitize the somatotroph? Interpretation of responses of growth hormone during and after 10-hour infusion of GRF 1-29 amide in man
Interaction of growth hormone-releasing factor (GRF) and 14 GRF analogs with vasoactive intestinal peptide (VIP) receptors of rat pancreas. Discovery of (N-Ac-Tyr1,D-Phe2)-GRF(1-29)-NH2 as a VIP antagonist
VIP antagonist [N-Ac-Tyr1,D-Phe2]-GRF-(1-29)-NH2: an inhibitor of vasodilation in the feline colon
Effects of GRF (1-29) NH2 on short-term memory: neuroendocrine and neuropsychological assessment in healthy young subjects
An analogue of growth hormone releasing factor (GRF), (Ac-Try1, D-Phe2)-GRF-(1-29), specifically antagonizes the facilitation of the flexor reflex induced by intrathecal vasoactive intestinal peptide in rat spinal cord
A comparison of the biological activities of authentic rat GRF(1-43)OH with the analogue rat GRF(1-29)NH2
Popular Stacks Including Sermorelin
Quick Facts
- Class
- GHRH Analog
- Tier
- A
- Evidence
- Strong
- Safety
- Well-Studied
- Updated
- Apr 2026
- Citations
- 30PubMed
Also known as
Tags
Peptide Families
Related Goals
Conditions Discussed
Evidence Score
Clinical Trials
View Clinical TrialsLinks to ClinicalTrials.gov for reference. Listing does not imply endorsement.